New Delhi [India], April 20: Park Medi World Ltd is drawing investor attention as its aggressive capacity expansion, improving operating metrics, and favourable patient mix position the stock for medium-term re-rating. With a current market price of ₹225 and a target price of ₹300, the company presents a compelling growth story within India's hospital sector.
The North India-focused healthcare chain currently operates 14 NABH-accredited hospitals with around 3,250 beds, up significantly from 2,550 beds in FY23. The company has outlined a clear roadmap to scale capacity to approximately 5,260 beds by FY28, with a long-term ambition of reaching nearly 10,000 beds. This expansion is being driven through a mix of greenfield projects and acquisitions, primarily within its cluster-based operating model, which enhances asset utilisation and cost efficiencies.
A key driver for earnings improvement is the ongoing shift towards high-value specialties such as cardiology, oncology, and neurology. This transition has already boosted average revenue per occupied bed (ARPOB) to ₹27,406 in 9M FY26, alongside reduced average length of stay, indicating improved operational efficiency.
Additionally, a gradual shift in payer mix towards private and self-paying patients—now contributing around 17% of revenues—along with recent hikes in Central Government Health Scheme (CGHS) rates, is expected to support realisations and margin expansion.
Despite near-term pressures from new capacity ramp-up and dependence on government schemes, Park Medi's capital-efficient model—featuring low capex per bed and quick break-even timelines—provides resilience. The company is also expected to generate free cash flows even after planned capex of ₹620 crore, with a focus on reducing leverage.
Overall, while execution risks remain amid rapid expansion, consistent operational improvements and strong demand in Tier-II markets position Park Medi World as a structurally growing healthcare play with improving earnings visibility.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor